A B S T R A C T
Two recent matched cohort studies from the USA and Norway published in 2014 have raised some concerns related to the long-term safety of kidney living donation. Further studies on the long-term risks of living donation have since been published. In this position paper, Developing Education Science and Care for Renal Transplantation in European States (DESCARTES) board members critically review the literature in an effort to summarize the current knowledge concerning longterm risks of kidney living donation to help physicians for decision-making purposes and for providing information to the prospective live donors. Long-term risk of end-stage renal disease (ESRD) can be partially foreseen by trying to identify donors at risk of developing 'de novo' kidney diseases during life post-donation and by predicting lifetime ESRD risk. However, lifetime risk may be difficult to assess in young donors, especially in those having first-degree relatives with ESRD. The study from Norway also found an increased risk of death after living donor nephrectomy, which became visible only after >15 years of post-donation follow-up. However, these findings are likely to be largely the result of an overestimation due to the confounding effect related to a family history of renal disease. DESCARTES board members emphasize the importance of optimal risk-benefit assessment and proper information to the prospective donor, which should also include recommendations on health-promoting behaviour post-donation.
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I N T R O D U C T I O N
Kidney transplantation with living donor organs is associated with longer graft and patient survival compared with deceased donor organs. Until recently, we have been reassured by the fact that the long-term risk of end-stage renal disease (ESRD) or death in living kidney donors is similar to or even smaller than the general population [1, 2] . However, because living donors are selected among the healthiest, their long-term outcomes should be better rather than equal to the general population. Two recent studies have tried to compare donors with healthy subjects rather than with the general population [3, 4] . The findings of these studies have raised some concerns related to the long-term safety of living donation. Further studies on the longterm risks of living donation have since been published. In this position paper, Developing Education Science and Care for Renal Transplantation in European States (DESCARTES) board members critically reviewed the most recent literature concerning the long-term risk estimates of living donation. The present article represents an effort to summarize the current knowledge that may aid physicians in decision-making and in providing information to prospective live donors.
B A L A N C I N G R I S K S A N D B E N E F I T S O F L I V I N G D O N A T I O N
There is unanimous agreement that all transplant teams should make every possible effort to help prospective donors make an informed decision by providing them with quantitative risk estimates [5, 6] . If the risks are unknown, adequate and informed decision-making is almost impossible. When prospective donors are faced with an unknown risk, they may be unable to rationally decide, and the transplant team has a difficult task in balancing the risks and benefits of living donation [5, 6] .
Meanwhile, physicians should recognize that donors may also benefit, which adds another perspective for justifying living organ donation [7] . In order to recommend a person as an acceptable organ donor, a physician should first ascertain that the benefits for the potential donor are sufficient to offset the risks [7] . Such a framework can minimize conflicts of interest for the physician [7] . Although organ donation provides no physical benefit for donors, it may afford psychological gratification [7, 8] . The psychological benefit can be very large and at least as important as the physical benefit to the recipient. Typical examples are a parent who wants to see his/her child return to a normal life, a spouse seeing his/her loved one sharing the joys of life or an altruistic donor who starts a chain of transplantations allowing a number of patients to undergo successful transplant procedures that would otherwise be impossible to accomplish. Importantly, the vast majority of donors are satisfied after donation and would do it again, supporting the living donation procedure [9] . Unjustified dismissal of potential donors might harm both the recipient and the donor [8, 10] .
Key to balancing benefits and risks is a comprehensive knowledge of the short-term as well as long-term risks of donor nephrectomy. In this article we especially focus on the evidence of any association between nephrectomy and the long-term risk of ESRD or death in the individual kidney donor.
Traditionally, the most basic concern in kidney donation has been the fact that nephrectomy halves the renal mass, raising the question whether the remaining kidney suffers in the long term from being overloaded with the extra work of the missing kidney.
Worries arose from the rat model of progression of renal diseases, whereby a substantial renal ablation (5/6 nephrectomy) causes glomerular hypertension (i.e. increase of glomerular transcapillary pressure). Glomerular hypertension causes albuminuria and eventually focal segmental glomerulosclerosis, leading to progressive renal failure [11] . Despite initial worries about the negative impact of extreme kidney mass reduction in humans [12] , a recent prospective study of 21 adult living kidney donors before, 1 and 6 years after donation suggests that the rat model of progression of renal disease does not apply to donor nephrectomy [13] . This study showed that the remaining kidney undergoes the expected adaptive hyperfiltration [40% increase in glomerular filtration rate (GFR)] [13] . Hyperfiltration occurs because of hyperperfusion and hypertrophy, which happen in parallel with hyperfiltration. However, the morphometric analysis, and the mathematical modelling of glomerular dynamics suggested that hyperfiltration occurred with no clear-cut contribution of glomerular hypertension [13] . This encouraging finding seems to be confirmed by a recent prospective follow-up control study [14, 15] carried out on 200 donors and healthy controls. At 36 months after donation, measured GFR (iohexol) continued to improve in donors, whereas controls had an expected age-related decline in renal function [15] . Unfortunately, these prospective studies have relatively short-term follow-up. Long-term follow-up of several decades can currently be accrued only by retrospective studies, with their inherent bias and difficulty in controlling for confounding issues.
Important to note in this respect is the fact that, with the availability of renin-angiotensin-aldosterone system (RAAS) blockade, glomerular hypertension and proteinuria due to hyperfiltration can be treated effectively [16] . Although no clinical studies in living donors exist, it can be assumed that the majority of donors who eventually will develop proteinuria and hypertension would nowadays be treated with RAAS blockers.
R E T R O S P E C T I V E S T U D I E S O N T H E L O N G -T E R M E S R D R I S K
To avoid bias in retrospective studies, it is critical that they include an appropriate control group of non-donating healthy subjects. Controls must represent the counterfactual experience of life without donation: what would have happened to donors if they had not donated. The best representatives of counterfactual life without donation are the non-donating siblings who share the same genetic and environmental background as the donors.
Indeed, the long-term effect of nephrectomy was originally investigated by studies that compared donors with their nondonating siblings [17, 18] . In these landmark studies there was no difference in albuminuria and blood pressure between donating and non-donating siblings after >10 and 20 years of follow-up. Creatinine clearance was only 10-20% lower in donors. However, the drawback of these studies is the small numbers of subjects, the largest one [18] recruiting only 50 non-donating siblings.
The only alternative to using siblings is to identify nondonating controls sharing nearly the same baseline risk factors as the donors. Large health surveys performed on the general population provide ideal pools from which these controls can
be sampled. Sampled controls must share the most important baseline risk factors, a procedure that may require the use of various and complex statistical tools. If, and only if, the matching procedure grants an identical distribution of the most important baseline prognostic factors between donors and matched controls, then the observed difference in outcome can be regarded as being caused by living donor nephrectomy. Table 1 gives the findings of the two large matched cohort studies performed so far that have raised recent concerns about the safety of donor nephrectomy. Overall, the estimates of the long-term effect of nephrectomy on the risk of developing ESRD were fairly consistent between the two studies. Indeed, the ESRD risk increased by 11 times in the Norwegian study by Mjøen et al. [3] and 8 times in the US study (Table 1 ) [4] . These estimates definitely reflect a large 'relative' increase in risk. However, as long as the reference risk is not taken into account, relative risk estimates do not give practical information about what matters the most to live donors, namely, the increase in the long-term 'absolute' risk. The reference absolute lifetime risk for ESRD in controls was in fact very small in both studies (0.06% and 0.04% in the Norwegian and US studies, respectively). Indeed, 11 times or 8 times a close-to-zero reference hazards yields only minor increases in the absolute risk: the difference between donors and controls in the average absolute risk was in fact <0.3% after 15 years in the US studies (i.e. >300 living donations need to occur to have one donor develop nephrectomy-related ESRD after 15 years; Table 1 ) [3, 4] .
In any event, because of a lack of overlap between donors and controls, in both studies controls could not be matched for some major baseline risk factors such as family history of renal disease, geographical area or year of inclusion in the study. These factors should be matched in the study design in order to ensure that controls have the same baseline distribution of genetic and environmental determinants of renal disease and that they share the same temporal trends of ESRD. Inadequate control for these confounding variables is undoubtedly a potential source of relevant bias in both studies. For example, in the Norwegian study, no matching for family history of renal disease could be performed despite 80% of the donors being firstdegree relatives of the recipients. The resulting uneven distribution of this important baseline risk factor might have led to overestimating the long-term adverse consequences of nephrectomy. Indeed, most of the donors developing ESRD did so because of new-onset immunologically mediated renal disease (i.e. genetic and environmentally determined diseases) rather than because of progressive chronic renal failure and focal segmental sclerosis (i.e. renal disease caused by reduced renal mass).
I D E N T I F Y I N G T H E P R O S P E C T I V E D O N O R S W H O A R E A T I N C R E A S E D L O N G -T E R M E S R D R I S K
Despite the risk of bias, the two studies discussed above nonetheless suggest that nephrectomy is associated with, albeit low, long-term risk of ESRD. While the effects of reduced renal mass can hardly explain the observed increased long-term ESRD risk, it is clear that a reduced post-donation renal reserve will advance the progression to ESRD when 'de novo' kidney diseases develop [19] . Whereas rare events such as renal cancer or trauma in the remaining kidneys cannot be foreseen, it is important to address if kidney donors have an additional risk beyond these unforeseen events. Therefore, the problem of assessing the long-term ESRD risk comes down to identify prospective donors at increased risk of developing renal diseases after donation.
These donors are mainly those with minor medical abnormalities (e.g. hypertension, obesity) or borderline characteristics (e.g. older age, borderline-normal GFR) at the time of donation. However, an increased risk may also be present in those with a normal pre-donation workup, especially in the case of young donor age. Indeed, it is particularly difficult to predict the medical consequences in the long-term (i.e. >30 years) for prospective donors below the age of, say, 25-35 years. Young donors who are at risk of developing renal diseases will be difficult to identify, as they may well have a normal pre-donation medical evaluation [20] . In fact, evaluation and donation may occur decades ahead of the manifestation of a primary renal disease (e.g. microhematuria/albuminuria or hypertension in IgA nephropathy) or the development of risk factors for renal failure, such as diabetes [20] . Young age might be a special concern in first-degree relatives of the donors. In fact, a study performed on the Norwegian general population by Skrunes et al. [21] showed that subjects with a first-degree relative with ESRD caused by non-hereditary diseases such as glomerulonephritis, pyelonephritis, diabetes or hypertension have a long-term risk of ESRD that is almost four times higher compared with subjects with no family history of renal disease. The findings from this large cohort study confirm those from previous studies [22, 23] . Therefore, nephrologists should inform young prospective donors having a first-degree relative with renal disease (e.g. brother with ESRD because of glomerulonephritis) that consanguinity in young donors can be regarded per se as a risk factor for the development of renal diseases despite a normal medical workup. African American race is an additional baseline risk indicator that might be taken into account when assessing young related donors with a normal workup [20, 24] .
In this context, it is also important to know that risk can be modified, for example, by a healthy lifestyle; by regular medical surveillance of renal function, proteinuria and blood pressure; and by timely and aggressive treatment of newly developed risk factors such as hypertension or albuminuria (e.g. with RAAS blockers). Patients have to be educated that by such measures the increased risk after living donation could be counterbalanced, although to date no study confirms this contention.
P R E D I C T I O N O F T H E R I S K O F D E V E L O P I N G E S R D I N T H E G E N E R A L H E A L T H Y P O P U L A T I O N
As outlined above, prospective donors at increased risk of renal disease after donation might be identified among those with various minor medical abnormalities or borderline characteristics. So far, no study has been specifically designed to assess the effect of individual donor risk factors in the context of all other risk factors that may exert an additive effect in increasing the overall risk of developing ESRD after donation [25] . However, a recent retrospective study that pooled the follow-up from various US cohorts (5 million subjects in total) estimated, via complex simulation models, the predicted lifetime risk of ESRD of every healthy individual. The model was based on 10 demographic and clinical characteristics, namely, age, gender, race, estimated GFR (eGFR), systolic blood pressure, antihypertensive medications, body mass index (BMI), non-insulin-dependent diabetes mellitus, urine albumin to creatinine ratio and smoking history [26] . The risk calculator, which is based on model estimates, is freely available on the web (www.transplant models.com/esrdrisk; 1 November 2016, date last accessed). It is useful to calculate the pre-donation lifetime risk in all donors, and might be particularly useful in the setting of prospective donors who present with various minor medical abnormalities, such as borderline-normal eGFR, hypertension and highnormal urine albumin:creatinine ratio. Such a calculation makes the risk of donation better quantifiable and may help the donor make an informed decision. For example, according to the risk calculator, a 40-year-old white, hypertensive, female subject with eGFR of 80 mL/min/1.73 m 2 , 130 mmHg systolic blood pressure on anti-hypertensive medication and with an otherwise unremarkable workup has a predicted pre-donation lifetime risk of ESRD of 0.73%. The predicted pre-donation risk for ESRD is 0.10% after 15 years. Unfortunately, the postdonation risk cannot be calculated with the calculator; therefore, the effect of donor nephrectomy cannot be predicted. However, based on this [26] and on a previous study [4] , it is likely that, on average, the ESRD risk is increased by nephrectomy by 3-5 times or by þ0.30% absolute risk 15 years after donation (e.g. from 0.10 to 0.40%, which is well below an absolute risk of 1% despite donor nephrectomy; for a quick reference concerning the post-donation change in the average risk, see Supplementary Table S5 from Supplementary Appendix of Grams et al. [26] ).
Besides not predicting post-donation risk, the calculator has two additional limitations. First, the prediction model for lifetime risk is based on a simulation study. In fact, the actual length of follow-up that was accrued to generate these simulations ranged between 4 and 16 years. Therefore, predictions may be less accurate for young donors, precisely those in whom these long-term predictions (>30 years) are of greatest interest with respect to lifetime ESRD risk estimations [27, 28] . Recently, Ibrahim et al. [29] published a study on the long-term risk of ESRD in a cohort of white live donors who were followed-up for an average of 17 (range 2-51) years. The authors examined the baseline determinants of the risk of developing chronic renal disease decades after donation and developed a-not yet validated-risk calculator based on a population of white donors (http://jasn.asnjournals.org/content/27/9/2885/ suppl/DCSupplemental; 1 November 2016, date last accessed). The estimates of the combined ESRD or eGFR <30 mL/min risk from this study appear consistent with the predictions for 15-year ESRD risk alone that can be obtained from subjects with similar characteristics using the live donor risk calculator by Grams et al. [26] . Second, the live donor risk calculator does not take into account a family history of renal disease [30] , which, as outlined above, is the most important ESRD risk indicator in young donors with normal workup at evaluation. Unfortunately, data on family history of renal disease were not available from the cohort and therefore could not be included in the prediction model [31] .
R E L I A B L E L O N G -T E R M E S R D R I S K P R E D I C T I O N S I N O L D E R D O N O R S
As outlined above, the long-term ESRD risk estimates that are currently available to guide decision-making are more reliable when applied to older as opposed to younger donors [27] . Recent studies provide further support to this notion by showing that the post-donation hazard of ESRD (i.e. the risk of ESRD during every year of post-donation follow-up) progressively increases 10 years post-donation when renal failure is caused by either diabetes or hypertension [32] . This late progressive increase, which might not have been detected by the studies published so far [3, 4] because of the insufficient length of follow-up, is less of an issue when evaluating the suitability of older donors [27] . In fact, current screening protocols invariably search for risk factors such as abnormal fasting blood glucose, albuminuria, hypertension, and reduced renal function. Older donors who are fated to develop advanced renal failure because of diabetic nephropathy or hypertensive nephrosclerosis might already have developed these abnormalities at the time of evaluation. For example, by the age of 65 years virtually all the subjects that will eventually develop ESRD or near-ESRD due to diabetes during their remaining lifespan will show increase fasting blood glucose and albuminuria at the time of their living donor workup. If they develop diabetes later in life, they will not have enough time to develop advanced renal disease because of the limited life expectancy. Therefore, unlike their younger counterparts, older candidates will have their lifetime ESRD risk greatly decreased by current screening protocols [27] . Indeed, evidence published so far shows that living donation from older donors appears safe [25, [33] [34] [35] [36] and that the recipient outcomes are generally good [37, 38] . Therefore, we believe that the practice of evaluating older donors should be encouraged.
T H E E F F E C T O F N E P H R E C T O M Y O N L O N G -T E R M R I S K O F D E A T H
Mjøen et al. [3] found that nephrectomy increases long-term mortality of live donors and that this effect is visible only after 15 years of follow-up, a time span that could not be explored by previous studies [3] . This surprising finding is difficult to explain by the consequences of nephrectomy alone. Table 2 lists the mechanisms that might be theoretically responsible for the increased long-term risk of death, which are grouped by those that relate to an increased risk of renal failure after donation and those that relate to abnormalities that develop because of post-donation low-normal GFR. Previously we mentioned the importance of identifying prospective donors at risk of developing post-donation 'de novo' kidney diseases, as these may lead to 'chronic' renal failure, which is associated with an increased risk of death. On the other hand, as shown in Table 2 , there is no evidence so far that nephrectomy increases the risk of developing, in the long-term, 'acute' renal failure episodes (e.g. because of kidney stones [39] or acute kidney injury [40] ). More intriguing are the subtle abnormalities that develop after nephrectomy because of the resulting low-normal GFR, such as increased arterial blood pressure [15, 41] , and increased levels of parathyroid hormone [14, 15] , homocysteine [14, 15] and uric acid [42] . Whether or not the latter laboratory abnormalities adversely affect the long-term risk of death is a controversial issue [43] [44] [45] . However, even though they may indeed develop after donation, they are minor and non-progressive and therefore can hardly explain the increased long-term risk of death. On the other hand, an increase in plasma endothelin [46] , asymetric dimethylarginine (ADMA; a strong cardiovascular risk factor) [47] , and left ventricular mass and a decrease in aortic distensibility have all been described shortly after nephrectomy [48, 49] . The clinical relevance of these findings appear to be questioned by the results of the study by Garg et al. [50] , who showed no increase whatsoever in the risk of cardiovascular events in living donors up to 10 years post-donation.
Overall, the evidence published so far does not provide a clear rationale for the increased risk of death observed over the long-term follow-up in the study by Mjøen et al. [3] .
R I S K O F B I A S O F T H E E S T I M A T E D E F F E C T O F D O N O R N E P H R E C T O M Y O N M O R T A L I T Y
Just like with the risk of ESRD, the long-term risk of death must be assessed by retrospective studies examining the counterfactual experience without donation: what would have happened to donors if they had not donated? The longest follow-up ever, 45 years after nephrectomy, was examined in a study by Narkun-Burgess et al. [51] . In this study, the long-term effect of nephrectomy was examined by comparing US Army personnel who lost a kidney due to trauma during World War II (62 subjects, the majority of whom were white) with a group of Army enlisted men who bought National Life Insurance policies during their World War II military service. Nephrectomy had no adverse effect on survival, which was identical between nephrectomized servicemen and controls, with an almost entire lifespan follow-up. It is worth noting that in this study subjects were young at the time of nephrectomy (average age 25 years), but they did not have a family history for renal disease [51] .
The study by Segev et al. [52] was the first comparing the survival of US donors (>80 000) with 1:1 matched healthy donors rather than the general population. The study showed that nephrectomy did not have any adverse effect on mortality. However, the median follow-up was only 6 years (interquartile range [3] [4] [5] [6] [7] [8] [9] [10] . In contrast to this US study, the Norwegian study by Mjøen et al. [3] , which had a much longer follow-up, found that nephrectomy causes a 30% increase in mortality in the long term (i.e. 1.3 relative risk). At first glance, a relative risk of 1.3 might look like a small risk increase. In fact, because the reference risk (mortality) was high among the controls (almost 15% 25-year cumulative mortality), the increase in absolute risk was large. After 20-25 years, nephrectomy was associated with an increase of 5% in the absolute risk of dying. We hold the opinion that this 'plus 5% mortality' might be an overestimation due to the confounding effect related to a family history of renal disease (80% of the donors were first-degree relatives of the recipients). Indeed, not only the baseline risk of ESRD is increased in patients having a first-degree relative with ESRD, but so is the baseline risk of death [21] . In the study performed in the Norwegian population by Skrunes et al. [21] , the relative risk of death associated with a family history of renal disease was 1.10 (i.e. 10% increase). This might look like a trivial increase, but as shown in Figure 1 , the impact is far from being negligible. If we apply, under the proportional hazard assumption, the relative risk of 1.10 associated with a family history of renal disease to the matched controls of the study of Mjøen et al. [3] , their baseline risk increases substantially. This increase, depicted as an upward shift of the mortality function line in Figure 1 , reflects the potential bias in this study. As a consequence, the true adverse effect of nephrectomy on mortality is difficult to determine and further studies on this issue are required before making definite conclusions.
Apart from bias, it is worth noting that 40% of the Norwegian donors and controls were smokers. It is known that smoking not only dramatically increases the risk of death but also increases the risk of renal insufficiency [39] [40] [41] . We believe that prospective donors have to be informed about the potentially increased long-term risks and educated about counteracting measures, e.g. cessation of smoking.
Pregnancy complication in women with a single kidney after living donation is one of the major concerns expressed by young women who are considering donation. In this regard, European renal best practice (ERBP) guidelines, which are based on studies published up to 2009 [53] [54] [55] [56] , 'recommends informing women of childbearing age that they are selected from a very healthy subpopulation and donation increases their individual risk from below that of the general population to that of the general population' [25] . A matched cohort study published after the publication of those guidelines provided further support to the ERBP recommendation, by suggesting that the incidence of gestational hypertension and pre-eclampsia might be increased in kidney donors compared with non-donors [57] . The study found that the absolute risk of gestational hypertension or preeclampsia increases from 4.8% to 11.5% because of nephrectomy. The increase in risk of these complications in donors versus non-donors was significantly higher among those >32 years of age than in younger women. However, nephrectomy did not affect the incidence of any other pregnancy complication (such as caesarean section, post-partum haemorrhage, preterm birth, low birthweight, stillbirths, maternal or neonatal deaths).
Because the available studies point towards a somewhat higher risk of gestational hypertension and pre-eclampsia, it is important to inform potential donors on this risk. However, it is also important to note that such complications can be treated. In fact, overall outcome of pregnancies post-donation in those studies was good.
C O N C L U S I O N S
After critically examining the current evidence on long-term risks of living donation, the DESCARTES working group holds the opinion that living kidney donation should be regarded as an acceptable procedure, as the long-term risks for the donor are generally low and in many instances they are largely offset by the overall benefit for the donor and recipient. Since long-term risks, which vary depending on the donor's profile, can be partially foreseen, the transplant team should make every effort to assess them in the prospective donor and help the donor make a properly informed decision. The availability of a web-based risk calculator (e.g. www.transplantmodels.com/esrdrisk; 1 November 2016, date last accessed) should be advertised. However, donors should be aware that in some cases lifetime risks may be difficult The figure represents the observed mortality in the study by Mjøen et al. [3] in donors (red line) and controls (blue line). Applying a relative risk of 1.10 to 80% of the controls (i.e. the proportion with a first-degree relative with ESRD), under the proportional hazard assumption, the blue line shifts upwards to the dotted blue line, which represents the mortality that would have been observed in the matched controls had the study been adjusted for consanguinity. The distance between the dotted and solid blue line can be regarded as the potential bias in this study, caused by the fact that controls were 'too good' compared with donors because of a less frequent family history of ESRD. The vertical light blue dotted line represents the median follow-up of the study by Segev et al. [4] , underlining the fact that the timespan of this study was much shorter than that of the study by Mjøen et al. [3] .
to predict. This is especially true for young donors with a risky genetic and environmental background. The transplant team should also inform the donor that a healthy lifestyle postdonation and outpatient clinic follow-up may offer substantial protection for donor health in the long-term (see Informed Consent in the Supplementary Appendix).
Additional studies are needed to better focus on risks of lifetime ESRD and death in young donors with a risky genetic and environmental background. In addition to efforts to track the follow-up of all (particularly the young) donors, new studies could also focus on whether or not the lifetime risks can actually be reduced by the current donor exclusion protocols [27] and modified by appropriate post-donation interventions.
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